vs

Side-by-side financial comparison of HUTCHMED (China) Ltd (HCM) and Verisign (VRSN). Click either name above to swap in a different company.

Verisign is the larger business by last-quarter revenue ($425.3M vs $270.8M, roughly 1.6× HUTCHMED (China) Ltd). Verisign runs the higher net margin — 48.5% vs 0.7%, a 47.8% gap on every dollar of revenue. On growth, Verisign posted the faster year-over-year revenue change (7.6% vs -16.5%). Verisign produced more free cash flow last quarter ($285.1M vs $3.4M).

HUTCHMED (China) Ltd is a biopharmaceutical firm focused on discovering, developing and commercializing targeted and immunotherapies for oncology and immunological diseases. It operates across China and global markets, with multiple marketed oncology drugs and a robust pipeline of late-stage clinical candidates addressing unmet patient needs.

Verisign, Inc. is an American company based in Reston, Virginia, that operates a diverse array of network infrastructure, including two of the Internet's thirteen root nameservers, the authoritative registry for the .com, .net, and .name generic top-level domains and the .cc country-code top-level domains, and the back-end systems for the .jobs and .edu sponsored top-level domains.

HCM vs VRSN — Head-to-Head

Bigger by revenue
VRSN
VRSN
1.6× larger
VRSN
$425.3M
$270.8M
HCM
Growing faster (revenue YoY)
VRSN
VRSN
+24.1% gap
VRSN
7.6%
-16.5%
HCM
Higher net margin
VRSN
VRSN
47.8% more per $
VRSN
48.5%
0.7%
HCM
More free cash flow
VRSN
VRSN
$281.7M more FCF
VRSN
$285.1M
$3.4M
HCM

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
HCM
HCM
VRSN
VRSN
Revenue
$270.8M
$425.3M
Net Profit
$2.0M
$206.2M
Gross Margin
37.7%
88.5%
Operating Margin
-13.2%
67.0%
Net Margin
0.7%
48.5%
Revenue YoY
-16.5%
7.6%
Net Profit YoY
-83.6%
7.7%
EPS (diluted)
$0.00

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
HCM
HCM
VRSN
VRSN
Q4 25
$270.8M
$425.3M
Q3 25
$419.1M
Q2 25
$277.7M
$409.9M
Q1 25
$324.5M
$402.3M
Q4 24
$395.4M
Q3 24
$390.6M
Q2 24
$305.7M
$387.1M
Q1 24
$384.3M
Net Profit
HCM
HCM
VRSN
VRSN
Q4 25
$2.0M
$206.2M
Q3 25
$212.8M
Q2 25
$455.0M
$207.4M
Q1 25
$11.9M
$199.3M
Q4 24
$191.5M
Q3 24
$201.3M
Q2 24
$25.8M
$198.8M
Q1 24
$194.1M
Gross Margin
HCM
HCM
VRSN
VRSN
Q4 25
37.7%
88.5%
Q3 25
88.4%
Q2 25
0.1%
88.0%
Q1 25
48.0%
87.7%
Q4 24
87.8%
Q3 24
88.0%
Q2 24
41.1%
87.8%
Q1 24
87.2%
Operating Margin
HCM
HCM
VRSN
VRSN
Q4 25
-13.2%
67.0%
Q3 25
67.8%
Q2 25
-1.3%
68.5%
Q1 25
-5.0%
67.4%
Q4 24
66.7%
Q3 24
68.9%
Q2 24
-9.0%
68.8%
Q1 24
67.4%
Net Margin
HCM
HCM
VRSN
VRSN
Q4 25
0.7%
48.5%
Q3 25
50.8%
Q2 25
163.8%
50.6%
Q1 25
3.7%
49.5%
Q4 24
48.4%
Q3 24
51.5%
Q2 24
8.4%
51.4%
Q1 24
50.5%
EPS (diluted)
HCM
HCM
VRSN
VRSN
Q4 25
$0.00
Q3 25
Q2 25
$0.52
Q1 25
$0.01
Q4 24
Q3 24
Q2 24
$0.03
Q1 24

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
HCM
HCM
VRSN
VRSN
Cash + ST InvestmentsLiquidity on hand
$1.4B
$580.5M
Total DebtLower is stronger
$93.2M
Stockholders' EquityBook value
$1.2B
$-2.2B
Total Assets
$1.8B
$1.3B
Debt / EquityLower = less leverage
0.08×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
HCM
HCM
VRSN
VRSN
Q4 25
$1.4B
$580.5M
Q3 25
$617.7M
Q2 25
$1.4B
$593.8M
Q1 25
$836.1M
$648.5M
Q4 24
$599.9M
Q3 24
$644.9M
Q2 24
$802.5M
$689.9M
Q1 24
$924.7M
Total Debt
HCM
HCM
VRSN
VRSN
Q4 25
$93.2M
Q3 25
Q2 25
$93.4M
Q1 25
$82.8M
Q4 24
Q3 24
Q2 24
$82.1M
Q1 24
Stockholders' Equity
HCM
HCM
VRSN
VRSN
Q4 25
$1.2B
$-2.2B
Q3 25
$-2.1B
Q2 25
$1.2B
$-2.0B
Q1 25
$759.9M
$-2.0B
Q4 24
$-2.0B
Q3 24
$-1.9B
Q2 24
$740.1M
$-1.8B
Q1 24
$-1.6B
Total Assets
HCM
HCM
VRSN
VRSN
Q4 25
$1.8B
$1.3B
Q3 25
$1.4B
Q2 25
$1.8B
$1.4B
Q1 25
$1.3B
$1.4B
Q4 24
$1.4B
Q3 24
$1.5B
Q2 24
$1.3B
$1.5B
Q1 24
$1.7B
Debt / Equity
HCM
HCM
VRSN
VRSN
Q4 25
0.08×
Q3 25
Q2 25
0.08×
Q1 25
0.11×
Q4 24
Q3 24
Q2 24
0.11×
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
HCM
HCM
VRSN
VRSN
Operating Cash FlowLast quarter
$8.2M
$289.6M
Free Cash FlowOCF − Capex
$3.4M
$285.1M
FCF MarginFCF / Revenue
1.2%
67.0%
Capex IntensityCapex / Revenue
1.8%
1.1%
Cash ConversionOCF / Net Profit
4.21×
1.40×
TTM Free Cash FlowTrailing 4 quarters
$-96.2M
$1.1B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
HCM
HCM
VRSN
VRSN
Q4 25
$8.2M
$289.6M
Q3 25
$307.7M
Q2 25
$-72.9M
$202.5M
Q1 25
$40.3M
$291.3M
Q4 24
$231.5M
Q3 24
$253.4M
Q2 24
$-39.8M
$160.4M
Q1 24
$257.3M
Free Cash Flow
HCM
HCM
VRSN
VRSN
Q4 25
$3.4M
$285.1M
Q3 25
$303.0M
Q2 25
$-82.2M
$194.7M
Q1 25
$32.5M
$285.5M
Q4 24
$222.0M
Q3 24
$247.8M
Q2 24
$-49.9M
$151.2M
Q1 24
$253.5M
FCF Margin
HCM
HCM
VRSN
VRSN
Q4 25
1.2%
67.0%
Q3 25
72.3%
Q2 25
-29.6%
47.5%
Q1 25
10.0%
71.0%
Q4 24
56.1%
Q3 24
63.4%
Q2 24
-16.3%
39.1%
Q1 24
66.0%
Capex Intensity
HCM
HCM
VRSN
VRSN
Q4 25
1.8%
1.1%
Q3 25
1.1%
Q2 25
3.3%
1.9%
Q1 25
2.4%
1.4%
Q4 24
2.4%
Q3 24
1.4%
Q2 24
3.3%
2.4%
Q1 24
1.0%
Cash Conversion
HCM
HCM
VRSN
VRSN
Q4 25
4.21×
1.40×
Q3 25
1.45×
Q2 25
-0.16×
0.98×
Q1 25
3.38×
1.46×
Q4 24
1.21×
Q3 24
1.26×
Q2 24
-1.54×
0.81×
Q1 24
1.33×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons